Sitagliptin (Januvia™) is a new oral agent approved by the US FDA to treat Type 2 diabetes. This is the first approved agent in a new class of antihyperglycemics, dipeptidyl peptidase (DPP)-4 ...

Get detailed information on Sitagliptin, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated prescription ...

Merck & Co has been fighting to defend its blockbuster type 2 diabetes therapy Januvia from generic competition for years, and a new judgment looks set to protect its third biggest-selling drug ...

Get detailed information on Sitagliptin-Metformin, including pronunciation, uses, dosage guidelines, indications, and instructions on how and when to take it and when to avoid it. The updated ...

Expert Rev Endocrinol Metab. 2008;3(6):691-697. Elimination of sitagliptin occurs primarily via renal excretion (79%) and involves active tubular secretion. Sitagliptin is a substrate for human ...